Pharmacokinetics of the prototype and hydrolyzed carboxylic forms of ginkgolides A, B, and K administered as a ginkgo diterpene lactones meglumine injection in beagle dogs
-
Add time:08/08/2019 Source:sciencedirect.com
Ginkgo diterpene lactones meglumine injection (GDLI) is a commercially available product used for neuroprotection. However, the pharmacokinetic properties of the prototypes and hydrolyzed carboxylic forms of the primary components in GDLI, i.e., ginkgolide A (GA), ginkgolide B (GB), and ginkgolide K (GK), have never been fully evaluated in beagle dogs. In this work, a simple, sensitive, and reliable method based on ultra-fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) was developed, and the prototypes and total amounts of GA, GB, and GK were determined in beagle dog plasma. The plasma concentrations of the hydrolyzed carboxylic forms were calculated by subtracting the prototype concentrations from the total lactone concentrations. For the first time, the pharmacokinetics of GA, GB, and GK were fully assessed in three forms, i.e., the prototypes, the hydrolyzed carboxylic forms, and the total amounts, after intravenous administration of GDLI in beagle dogs. It was shown that ginkgolides primarily existed in the hydrolyzed form in plasma, and the ratio of hydrolysates to prototype forms of GA and GB decreased gradually to a homeostatic ratio. All of the three forms of the three ginkgolides showed linear exposure of AUC to the dosages. GA, GB, and GK showed a constant half-life approximately 2.7, 3.4, and 1.2 h, respectively, which were consistent for the forms at three dose levels (0.3, 1.0, and 3.0 mg·kg−1) and after a consecutive injection of GDLI for 7 days (1.0 mg·kg−1).
We also recommend Trading Suppliers and Manufacturers of Ginkgolide A (cas 15291-75-5). Pls Click Website Link as below: cas 15291-75-5 suppliers
Prev:Ginkgolide B functions as a determinant constituent of Ginkgolides in alleviating lipopolysaccharide-induced lung injury
Next:Ginkgolides-loaded soybean phospholipid-stabilized nanosuspension with improved storage stability and in vivo bioavailability) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Ginkgolide A (cas 15291-75-5) ameliorates non-alcoholic fatty liver diseases on high fat diet mice08/10/2019
- Ginkgolides-loaded soybean phospholipid-stabilized nanosuspension with improved storage stability and in vivo bioavailability08/09/2019
- Ginkgolide B functions as a determinant constituent of Ginkgolides in alleviating lipopolysaccharide-induced lung injury08/07/2019
- Ginkgolide C reduced oleic acid-induced lipid accumulation in HepG2 cells08/06/2019
- Characterizations of the hydrolyzed products of Ginkgolide A (cas 15291-75-5) and ginkgolide B by liquid chromatography coupled with mass spectrometry08/05/2019
- Formulation and evaluation of gastric-floating controlled release tablets of Ginkgolides08/04/2019
- Pharmacokinetics and tissue distribution of Ginkgolide A (cas 15291-75-5), ginkgolide B, and ginkgolide K after intravenous infusion of ginkgo diterpene lactones in a rat model08/03/2019
-
Health and Chemical more >
-
Related Products